Paliperidone palmitate is a long-acting injectable atypical antipsychotic used for the treatment of schizophrenia and schizoaffective disorder. It is an ester prodrug of paliperidone that slowly releases the active drug after intramuscular injection, providing sustained dopamine (D₂) and serotonin (5-HT₂A) receptor blockade. It is grouped under the following drug class(es): Mood stabilizers and Psychotropic agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Invega Sustenna, xeplion and Invega Trinza. Its PubChem CID is 9852746.
Paliperidone palmitate
| CAS No | 199739-10-1 |
|---|---|
| Molecular Formula | C39H57FN4O4 |
| Molecular Weight | 664.9 g/mol |
| Synonyms | [3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl] hexadecanoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Paliperidone palmitate is a long-acting injectable atypical antipsychotic used for the treatment of schizophrenia and schizoaffective disorder.
The listed CAS number is 199739-10-1.
The listed molecular formula is C39H57FN4O4.
The listed molecular weight is 664.9 g/mol.
[3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl] hexadecanoate.
The source lists Invega Sustenna, xeplion and Invega Trinza.